TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I or II~* Scheduled for surgery under general anesthesia.~Exclusion Criteria:~* Predicted difficult airway~* Severe neurologic or cardiologic conditions~* Recent upper airway infectious diseases

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- Study arm (Type: EXPERIMENTAL): There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Music Intervention on Migraine Headaches

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with episodic migraine with at least 4 attacks per month~* Patients with migraines with or without aura with diagnostic criteria per International Headache Society~* Patients with a migraine for more than one year~* Diagnosis age \< 50 years~* Patients with an available internet connexion to access Music Care application~* Patients with minimal knowledge in informatics~* Patients who sign their inform consent~Exclusion Criteria:~* Patients aged less than 18 years~* Patients with chronic migraine~* Patients with epilepsy~* Patients with a deficiency on auditive function~* Patients with a disease that could be fatal within the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Music intervention (Type: OTHER): The music intervention is administered via a smartphone- (and computer-) based application called Music Care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* 25(OH) D3 level \< 80 ng/mL~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2~* Creatinine ≤ 2.0 mg/dL~* Corrected serum calcium ≤ 10.5 mg/dL~Exclusion criteria:~* History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue)~* Hypersensitivity to cholecalciferol or one of its components~PRIOR CONCURRENT THERAPY:~* No other concurrent vitamin D supplementation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
- Arm II (Type: EXPERIMENTAL): Patients receive 6,000 IU of vitamin D3 once daily.
- Arm III (Type: EXPERIMENTAL): Patients receive 8,000 IU of vitamin D3 once daily.
- Arm IV (Type: EXPERIMENTAL): Patients receive 10,000 IU of vitamin D3 once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients aged 20 years old and over~2. ECOG \<3~3. Moderate or severe pain intensity with stable titration from previous opioid analgesics, 7 days at least prior to enrolment and with the dose equivalent to oral morphine ranging from 60 to 120 mg/day in previous treatment~4. Cancer-related pain that requires treatment with continuous around-the-clock strong opioid analgesic~5. Patients who are going to start Transtec treatment per clinical judgment, according to the locally approved labeling, are eligible.~6. Patients who are able to communicate and fill out the questionnaire forms~7. Patient provided signed informed consent~Exclusion Criteria:~1. Patients diagnosed with non-cancer pain or unexplained pain~2. Patients who have constipation (CTCAE grade 3 and above)~3. Patients with uncontrolled or unstable cardiac disease~4. Abnormal lab results, with obvious clinical significance, such as ALT or AST\>= 3 fold of upper limit of normal value or liver function of Child C grade prior to study~5. ALT or AST \>= 5 fold of upper limit of normal value for patients with liver metastasis or primary liver cancer~6. Pregnant or nursing (lactating) women~7. Patients who are drug or alcohol abuse~8. Patients who have hypersensitivity to buprenorphine~9. Patients who are clinically unstable or have a life expectancy of less than 8 weeks making completion of the trial unlikely~10. With any contraindications or using prohibited medication per locally approved

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18+;~* Self-reported annual household income less than $39,500 (at least 75% of participants - defined as low income household by the PEW Research Center);~* Racial/ethnic minority (at least 75% of participants must be non-white, with at least 50% identifying as Black/African American);~* Be a new or expectant mother - participants must be at least 28 weeks/6 months pregnant (3rd trimester), and up to 6 months post-birth (no more than 10% of participants will be currently pregnant, at least 90% will be postpartum).~* Able to comply with the terms of the study (available time commitment, have internet access; willing to comply with the specified focus groups and survey); and~* Able to read, write and speak English (all research and product development activities will be conducted in English due to budgetary constraints).~Exclusion Criteria:~* Unable to comply with the Inclusion Criteria~* Did not have a live birth (for those who are post-birth)~* Self-reported major medical/health issue which would impact participants' health or ability to participate.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fourth Trimester Mobile Tool (Type: OTHER): Fourth Trimester Mobile Tool

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) between 30.0-40.0 kg/m2~* Stable body weight (below 5 kg body weight change during past 3 month)~* Fasting plasma glucose below 7.0 mmol/L~Exclusion Criteria:~* Presence or history of cancer or any clinically significant cardiac, metabolic, renal, gastrointestinal, hepatic, endocrine, dermatological, haematological, or psychiatric diseases or disorders, considered by the Investigator to have influence of the results of this trial~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Current or history of treatment with medications that may cause significant weight gain, within 12 months prior to screening~* Use of weight lowering pharmacotherapy within the last 3 months prior to trial start~* Previous or scheduled (during the trial period) surgical treatment for obesity~* Diagnosed type 1 or type 2 diabetes~* Smoking habitually as judged by the Investigator~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods if not sterile or post-menopausal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None
- E (Type: EXPERIMENTAL): None
- F (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults (male and female) 18 to 49 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.~2. Negative urine pregnancy test at Visit 1 for all female subjects who are of childbearing potential.~Exclusion Criteria:~1. Male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for at least 3 months after the last dose of investigational product.~2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Chronic medical conditions include human immunodeficiency virus, chronic hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C virus infection.~3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) to any vaccine.~4. History of microbiologically proven invasive disease caused by group B streptococcus (Streptococcus agalactiae).~5. Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the subject's participation in the study (through the last blood draw).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Lowest dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Middle dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Highest dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Lowest dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Middle dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Highest dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Placebo (Type: PLACEBO_COMPARATOR): Saline control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Phase (CP)-CML Ph+ patients with complete hematologic response (CHR) but without one log BCR-ABL reduction (BCR-ABL level \>10% IS) 3 months of imatinib 400mg treatment. (Imatinib transient dose adjustments due to Adverse Event (AEs) are allowed with a maximum of 2 weeks interruption of treatment with imatinib (cumulative) within the 3 month period before randomization). Imatinib monotherapy must have been started within 6 months of CP-CML diagnosis (Ph + /BCR-ABL detection)~* Currently tolerating imatinib 400mg QD. Patients with prior imatinib treatment interruption or dose reductions are required to be on treatment with 400 mg imatinib for two weeks immediately prior to randomization to ensure tolerance to imatinib~* Eastern Co-Operative Group (ECOG) performance status = 0 - 2~* Adequate renal function defined as serum creatinine ≤3 times the institutional upper limit of normal (ULN)~* Adequate hepatic function defined as: total bilirubin ≤2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the institutional ULN~Exclusion Criteria:~* Previous diagnosis of accelerated phase or blast crisis~* Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases at baseline bone marrow cytogenetic test, unless the same abnormalities were present at diagnosis. Patients with no evidence of clonal evolution, including those patients whose cytogenetic testing fails or bone marrow aspiration is a dry tap at 3 months, are eligible for the study~* Subjects with less than CHR after 3 months of imatinib treatment or lost CHR after initial achievement~* Documented T315I/A, F317L, or V299L mutations (if already available - not required for screening)~* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Imatinib (≥400 mg) (Type: ACTIVE_COMPARATOR): Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
- Arm 2: Dasatinib (100 mg) (Type: ACTIVE_COMPARATOR): Dasatinib 100 mg tablet by mouth QD up to 60 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Boys age ≥7 years with DMD confirmed clinically and by mutation analysis able to undergo cardiac magnetic resonance (CMR) without sedation~* LV EF ≥45% (+/-5%) by clinically-acquired echocardiography, nuclear scan or cardiac MRI done within 2 weeks of enrollment~Exclusion Criteria:~* Non-MR compatible implants~* Severe claustrophobia~* Gadolinium contrast allergy~* Kidney disease~* Prior use of or allergy to aldosterone antagonist~* Use of other investigational therapy.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
- Spironolactone (Type: ACTIVE_COMPARATOR): Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 7 to 12 years old (inclusive)~* Amblyopia associated with strabismus, anisometropia, or both~* Visual acuity in the amblyopic eye 19 to 71 letters on Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS©) (20/40 to 20/400 inclusive)~* Visual acuity in the sound eye 79 letters or better on E-ETDRS© (20/25 or better)~* Interocular difference \>=15 letters (3 lines)~* Spectacles, if needed, worn for at least 16 weeks or visual acuity documented to be stable~Inclusion Criteria for Optional Ancillary Study:~* Enrolled into the main study~* Refractive error in both eyes between -0.25 and +5.00D, inclusive (to avoid the need to adjust for refractive error)~* Birth weight \>1500 grams~* No history of Central Nervous System (CNS) disease (e.g. intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), meningitis, developmental abnormalities of the brain, hydrocephalus, cerebral palsy, hypoxic ischemic encephalopathy~Exclusion Criteria:~* Amblyopia treatment (other than spectacles) in the last 6 months~* Myopia (more than -0.25D spherical equivalent) in either eye

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Patching (Type: ACTIVE_COMPARATOR): Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and \>4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
- Atropine (Type: ACTIVE_COMPARATOR): Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Statin intolerant and statin tolerant~* Fasting LDL-C between 130 mg/dL and 220 mg/dL~* Fasting triglyceride less than or equal to 400 mg/dL~* Body mass index (BMI) between 18 and 45 kg/m2~Key Exclusion Criteria:~* History or current clinically significant cardiovascular disease~* History or current type 1 diabetes or uncontrolled type 2 diabetes~* Use of metformin or thiazolidinediones (TZD) within 3 months of screening~* History of joint symptoms difficult to differentiate from myalgia~* Uncontrolled hypothyroidism~* Liver disease or dysfunction~* Renal dysfunction or nephritic syndrome~* Gastrointestinal (GI) conditions or prior GI procedures~* HIV or AIDS~* History or malignancy~* History or drug or alcohol abuse within last 2 years~* Use of experimental or investigational drugs within 30 days of screening~* Use of ETC-1002 in a previous clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 120 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- ETC-1002 180 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- ezetimibe 10mg/day (Type: ACTIVE_COMPARATOR): Orally, once daily in morning as capsules
- ETC-1002 120 mg/day + ezetimibe 10mg/day (Type: EXPERIMENTAL): Orally, once daily in morning
- ETC-1002 180 mg/day + ezetimibe 10mg/day (Type: EXPERIMENTAL): Orally, once daily in morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus, treated with Lantus±SU; ≥5-year after diagnosis~* Aged 20-75 years~* Hemoglobin A1C ≥7.0%-≤10.0%~* Fasting plasma glucose ≤180 mg/dL at screening~* Stable treatment (±20%) with Lantus for 3 months or more prior to screening.~* Sulfonylurea dose stable for 3 months or more prior to screening~Exclusion criteria:~* Type 1 diabetes mellitus~* Pregnancy or lactation~* Hypersensitivity to Lixisenatide~* Severely uncontrolled glycemic situation~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery or inflammatory bowel disease~* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening~* History within the previous 6 months of myocardial infarction, stroke or heart failure requiring hospitalization or drug or alcohol abuse~* Uncontrolled/inadequately controlled hypertension at the time of screening, with a resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>95 mmHg~* Amylase and/or lipase \>3 times or aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP) \>2 times the upper limit of the normal laboratory range~* End-stage renal disease and/or dialysis and clinically relevant history of gastrointestinal disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen.
- Sitagliptin - Januvia (Type: ACTIVE_COMPARATOR): 50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete